United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - bromocriptine mesilate - oral tablet - 2.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - bromocriptine mesilate 5.7mg - 6mg equivalent to 5 mg bromocriptine, adjusted depending on the content of water;   - capsule - 5 mg - active: bromocriptine mesilate 5.7mg - 6mg equivalent to 5 mg bromocriptine, adjusted depending on the content of water   excipient: capsugel caramel g4icsa00117 lactose monohydrate maize starch opacode black s-1-8114 opacode black s-1-8115 purified talc stearic acid - prolactin dependent menstrual cycle disorders (amenorrhoea, oligomenorrhoea, galactorrhoea), and/or female infertility associated with hyperprolactinaemia or luteal phase deficiency: bromocriptine may normalise the menstrual cycle and/or induce ovulation without ovarian overstimulation. treatment with bromocriptine is not curative and it is not effective in treating ovarian failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bromocriptine mesilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; disodium edetate; colloidal anhydrous silica; maleic acid; magnesium stearate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Malta - English - Medicines Authority

generics uk limited station close, potters bar, herts, en6 1tl, united kingdom - bromocriptine mesilate - tablet - bromocriptine mesilate 2.5 mg - other gynecologicals

Ireland - English - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - bromocriptine mesilate - capsules hard - 5 mg milligram - bromocriptine

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - bromocriptine mesilate - capsule, hard - 5 mg milligram(s) - prolactine inhibitors; bromocriptine

United States - English - NLM (National Library of Medicine)

sandoz inc - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets, usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine mesylate tablets, usp treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets, usp therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets, usp are indicated in the treatment of acromegaly. bromocriptine mesylate tablets, usp therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately one-half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets, usp offers potential benefit before the effects of irradiation are manifested. bromocriptine mesylate tablets, usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinson's disease. as adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets, usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing "end of dose failure" on levodopa therapy. bromocriptine mesylate tablets, usp therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function ("on-off" phenomenon). continued efficacy of bromocriptine mesylate tablets, usp therapy during treatment of more than two years has not been established. data are insufficient to evaluate potential benefit from treating newly diagnosed parkinson's disease with bromocriptine mesylate tablets, usp. studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate tablets, usp-treated patients than in levodopa/carbidopa-treated patients. patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets, usp therapy. hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate, uncontrolled hypertension and sensitivity to any ergot alkaloids. in patients being treated for hyperprolactinemia, bromocriptine mesylate should be withdrawn when pregnancy is diagnosed ( see precautions, hyperprolactinemic states ). in the event that bromocriptine mesylate is reinstituted to control a rapidly expanding macroadenoma (see precautions, hyperprolactinemic states ) and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine mesylate must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. when bromocriptine mesylate is being used to treat acromegaly, prolactinoma, or parkinson’s disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. if it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine mesylate is considered to be medically contraindicated. the drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. if the drug is used in the postpartum period, the patient should be observed with caution.

United States - English - NLM (National Library of Medicine)

american health packaging - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets, usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine mesylate tablets, usp treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets, usp therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets, usp are indicated in the treatment of acromegaly. bromocriptine mesylate tablets, usp therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately one-half of patien